Please ensure Javascript is enabled for purposes of website accessibility

How ResMed Trounced Expectations in Q4

By Keith Speights – Aug 6, 2020 at 7:04AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The healthcare company got some help from the COVID-19 pandemic.

There were plenty of questions earlier this year about how the COVID-19 pandemic might impact ResMed (RMD -0.07%). It's fair to say that most of the concerns have been put to rest. ResMed's shares are up more than 20% year to date.

The company announced its fiscal 2020 fourth-quarter results after the market closed on Wednesday. Here are the highlights from ResMed's Q4 update.

Male healthcare provider standing with arms crossed while smiling.

Image Source: Getty Images.

By the numbers

ResMed reported revenue in the fourth quarter of $770.3 million, up 9% year over year. This result easily beat the consensus Wall Street revenue estimate of $746.9 million.

The company announced Q4 net income of $177.8 million, or $1.22 per share, based on generally accepted accounting principles (GAAP). This marked a big increase from ResMed's GAAP earnings of $68.8 million, or $0.48 per share, posted in the prior-year period.

ResMed's bottom line also improved tremendously on a non-GAAP basis. The company recorded adjusted earnings of $193.3 million, or $1.33 per share, compared to $137.6 million, or $0.95 per share, in the same period in 2019. This crushed the average analysts' adjusted earnings estimate of $1.08 per share.

Behind the numbers

The best news for ResMed in Q4 came from outside the Western hemisphere. Revenue in Europe, Asia, and other markets jumped 22% year over year on a constant-currency basis. The strong growth resulted from the COVID-19 pandemic driving increased demand for its ventilators.

ResMed's software-as-a-service (SaaS) revenue grew by 7% over the prior-year period. The company attributed this increase to "continued growth in resupply service offerings and stabilizing patient flow in out-of-hospital care settings."

Closer to home, ResMed's sales in the U.S., Canada, and Latin America (excluding its SaaS businesses) rose 4% year over year. The coronavirus outbreak also fueled this increase, with ResMed reporting higher sales for its mask products and rising demand for its ventilators. 

While the solid revenue growth helped boost the company's bottom line, ResMed also held the line on spending. Its selling, general, and administrative expenses fell 4% year over year in part because of savings on travel and in other areas resulting from the COVID-19 pandemic.

Looking ahead

ResMed CEO Mick Farrell stated, "Sleep labs and physician practices are reopening across many geographies, and we're seeing accelerated adoption of digital health solutions which supports our long-term strategy." That's encouraging for ResMed's prospects throughout the rest of 2020. However, the COVID-19 pandemic remains something of a wild card for the healthcare stock

One thing that ResMed shareholders can look forward to with certainty is the company's quarterly dividend. ResMed's board of directors declared a cash dividend of $0.39 per share payable on Sept. 4, 2020 to shareholder on record as of Aug. 20, 2020. 

Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends ResMed. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

ResMed Inc. Stock Quote
ResMed Inc.
$218.30 (-0.07%) $0.16

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.